Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: Role of mitogen activated protein kinase and phosphatidylinositol 3- kinase

Atherosclerosis

Volumn 142, Issue 1, 1999, Pages 47-56

  Niculescu, Florin ^a   Badea, Tudor ^a   Rus, Horea ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Aortic smooth muscle cells; Cell cycle; Mitogen activated protein kinase; Phosphatidylinositol 3 kinase; Terminal complement complexes

Indexed keywords

CYCLIN DEPENDENT KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P21; UNCLASSIFIED DRUG; WORTMANNIN;

AORTA MEDIA; ARTICLE; CELL PROLIFERATION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ANALYSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RNA ANALYSIS; VASCULAR SMOOTH MUSCLE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; AORTA; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CELLS, CULTURED; COMPLEMENT ACTIVATION; COMPLEMENT MEMBRANE ATTACK COMPLEX; DNA; ENZYME ACTIVATION; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SMOOTH, VASCULAR;

EID: 0032890247     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00185-3     Document Type: Article

References (44)

1. Owens G.K. Regulation of differentiation of vascular smooth muscle cells. Physiol. Rev. 75:1995;487-517.
2. Parker T.G., Schneider M.D. Growth factors, proto-oncogenes, and plasticity of the cardiac phenotype. Ann. Rev. Physiol. 53:1991;179-200.
3. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:1993;801-809.
4. Fidler I.J., Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 79:1994;185-188.
5. Jackson C.L., Schwartz S.M. Pharmacology of smooth muscle cell replication. Hypertension. 20:1992;713-736.
6. Koyama H., Raines E.W., Bornfeldt K.E., Roberts J.M., Ross R. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell. 87:1996;1069-1078.
7. Sherr C.J. G1 phase progression: cycling on cue. Cell. 79:1994;551-555.
8. Xiong Y., Hannon G.J., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 366:1993;701-704.
9. el-Deiry W.S., Harper J.W., O'Connor P.M., Velculescu V.E., Canman C.E., Jackman J., Pietenpol J.A., Burrell M., Hill D.E., Wang Y. et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer. Res. 54:1994;1169-1174.
10. Stemme S., Hansson G.K. Immune mechanisms in atherogenesis. Ann. Med. 26:1994;141-146.
11. Niculescu F., Rus H.G., Vlaicu R. Immunohistochemical localization of C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis. Atherosclerosis. 65:1987;1-11.
12. Seifert P.S., Hugo F., Hansson G.K., Bhakdi S. Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab. Invest. 60:1989;747-754.
13. Guettier C., Hinglais N., Bruneval P., Kazatchkine M., Bariety J., Camilleri J.P. Immunohistochemical localization of S protein/vitronectin in human atherosclerotic versus arteriosclerotic arteries. Virchows. Archiv. A. Pathol. Anat. Histopathol. 414:1989;309-313.
14. Seifert P.S., Hugo F., Tranum-Jensen J., Zahringer U., Muhly M., Bhakdi S. Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J. Exp. Med. 172:1990;547-557.
15. Bhakdi S., Dorweiler B., Kirchmann R., Torzewski J., Weise E., Tranum-Jensen J., Walev I., Wieland E. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J. Exp. Med. 182:1995;1959-1971.
16. Rus H.G., Niculescu F., Constantinescu E., Cristea A., Vlaicu R. Immunoelectron-microscopic localization of the terminal C5b-9 complement complex in human atherosclerotic fibrous plaque. Atherosclerosis. 61:1986;35-42.
17. Rus H.G., Niculescu F., Porutiu D., Ghiurca V., Vlaicu R. Cells carrying C5b-9 complement complexes in human atherosclerotic wall. Immunol. Lett. 20:1989;305-310.
18. Shin M.L., Rus H.G., Niculescu F.I. Membrane attack by complement: assembly and biology of terminal complement complexes. Lee A.G. Biomembranes. 4:1996;123-149 JAI Press.
19. Niculescu F., Rus H., Shin S., Lang T., Shin M.L. Generation of diacylglycerol and ceramide during homologous complement activation. J. Immunol. 150:1993;214-224.
20. Niculescu F., Rus H., Shin M.L. Receptor-independent activation of guanine nucleotide-binding regulatory proteins by terminal-complement complexes. J. Biol. Chem. 269:1994;4417-4423.
21. Niculescu F., Rus H., Van Biesen T., Shin M.L. Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent. J. Immunol. 158:1997;4405-4412.
22. Shirazi Y., Rus H.G., Macklin W.B., Shin M.L. Enhanced degradation of messenger RNA encoding myelin proteins by terminal complement complexes in oligodendrocytes. J. Immunol. 150:1993;4581-4590.
23. DiScipio R.G., Smith C.A., Muller-Eberhard H.J., Hugli T.E. The activation of human complement component C5 by a fluid phase C5 convertase. J. Biol. Chem. 258:1983;10629-10636.
24. Carney D.F., Lang T.J., Shin M.L. Multiple signal messengers generated by terminal complement complexes and their role in terminal complement complex elimination. J. Immunol. 145:1990;623-629.
25. Rus H.G., Niculescu F., Shin M.L. Sublytic complement attack induces cell cycle in oligodendrocytes. S phase induction is dependent on c-jun activation. J. Immunol. 156:1996;4892-4900.
26. Gardner A.M., Lange-Carter C.A., Vaillancourt R.R., Johnson G.L. Measuring activation of kinases in mitogen-activated protein kinase regulatory network. Methods. Enzymol. 238:1994;258-270.
27. Vaillancourt R.R., Harwood A.E., Winitz S. Analysis of guanine nucleotides associated with protooncogene ras. Methods. Enzymol. 238:1994;255-258.
28. Coso O.A., Chiariello M., Kalinec G., Kyriakis J.M., Woodgett J., Gutkind J.S. Transforming G protein-coupled receptors potently activate JNK (SAPK). Evidence for a divergence from the tyrosine kinase signaling pathway. J. Biol. Chem. 270:1995;5620-5624.
29. Lazar D.F., Wiese R.J., Brady M.J., Mastick C.C., Waters S.B., Yamauchi K., Pessin J.E., Cuatrecasas P., Saltiel A.R. Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin. J. Biol. Chem. 270:1995;20801-20807.
30. Jiang Y., Chen C., Li Z., Guo W., Gegner J.A., Lin S., Han J. Characterization of the structure and function of a new mitogen- activated protein kinase (p38β). J. Biol. Chem. 271:1996;17920-17926.
31. Chirgwin J.M., Przybyla A.E., MacDonald R.J., Rutter W.J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 18:1979;5294-5299.
32. Thomas P.S. Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc. Natl. Acad. Sci. USA. 77:1980;5201-5205.
33. Gutkind S.J. The pathways connecting G protein-coupled receptors to nucleus through divergent mitogen-activated protein kinase cascades. J. Biol. Chem. 273:1998;1839-1842.
34. Morishita R., Gibbons G.H., Ellison K.E., Nakajima M., von der Leyen H., Zhang L., Kaneda Y., Ogihara T., Dzau V.J. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J. Clin. Invest. 93:1994;1458-1464.
35. Morishita R., Gibbons G.H., Ellison K.E., Nakajima M., Zhang L., Kaneda Y., Ogihara T., Dzau V.J. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. USA. 90:1993;8474-8478.
36. Michieli P., Chedid M., Lin D., Pierce J.H., Mercer W.E., Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer. Res. 54:1994;3391-3395.
37. Chang M.W., Barr E., Lu M.M., Barton K., Leiden J.M. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J. Clin. Invest. 96:1995;2260-2268.
38. Yang Z.Y., Simari R.D., Perkins N.D., San H., Gordon D., Nabel G.J., Nabel E.G. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc. Natl. Acad. Sci. USA. 93:1996;7905-7910.
39. Yamauchi K., Holt K., Pessin J.E. Phosphatidylinositol 3-kinase functions upstream of Ras and Raf in mediating insulin stimulation of c-fos transcription. J. Biol. Chem. 268:1993;14597-14600.
40. Hawes B.E., Luttrell L.M., van Biesen T., Lefkowitz R.J. Phosphatidylinositol 3-kinase is an early intermediate in the G beta gamma-mediated mitogen-activated protein kinase signaling pathway. J. Biol. Chem. 271:1996;12133-12136.
41. Lopez-Ilasaca M., Crespo P., Pellici P.G., Gutkind J.S., Wetzker R. Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase gamma. Science. 275:1997;394-397.
42. Edelmann H.M.L., Kuhne C., Petritsch C., Ballou L.M. Cell cycle regulation of p70 S6 kinase and p42/p44 mitogen-activated protein kinases in swiss mouse 3T3 fibroblasts. J. Biol. Chem. 271:1996;963-971.
43. Robinson C.J., Scott P.H., Allan A.B., Jess T., Gould G.W., Plevin R. Treatment of vascular smooth muscle cells with antisense phosphorothioate oligodeoxynucleotides directed against p42 and p44 mitogen-activated protein kinases abolishes DNA synthesis in response to platelet-derived growth factor. Biochem. J. 320:1996;123-127.
44. Benzaquen L.R., Nicholson-Weller A., Halperin J.A. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J. Exp. Med. 179:1994;985-992.